|
|
|
European Biopharmaceutical Review
|
'Robot' is a Czech word meaning worker, from the play RUR: Rossums' Universal Robots by the Bohemian writer Karel Capek. The robot has since become an inspiration for science fiction writers and for engineers. Of course the science fiction vision of a robot is a mechanical man, but the reality we see in industry is simply a robotic arm. This is a versatile programmable manipulator, an integration of mechanics, electronics and software, designed interdependently to produce the mechanical equivalent of the computer - an undedicated machine unable to do anything until we program it.
In the pharmaceutical lab it is even less than that definition; the term 'robot' being applied to programmable liquid handlers. Drug development requires the screening of hundreds or thousands of samples and it is in this field that the robot arm is a vital tool. Such an automated screening system is called a 'high-throughput screening' (HTS) system.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
5 |
| | | | | |
|
|
 |
Industry Events |
 |
Paediatric Clinical Trials
21-22 March 2012, Copthorne Tara Hotel, London, United Kingdom
Designing accurate and safe paediatric formulations is one of the topics being discussed at SMi’s Paediatric Clinical Trials held on 21st & 22nd March 2012
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|
